Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Long-Term Debt Repayments (2021 - 2022)

Tg Therapeutics (TGTX) has 2 years of Long-Term Debt Repayments data on record, last reported at -$975000.0 in Q1 2022.

  • For Q1 2022, Long-Term Debt Repayments changed N/A year-over-year to -$975000.0; the TTM value through Dec 2022 reached -$975000.0, changed N/A, while the annual FY2024 figure was -$107.6 million, N/A changed from the prior year.
  • Long-Term Debt Repayments reached -$975000.0 in Q1 2022 per TGTX's latest filing, up from -$15.4 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at -$975000.0 in Q1 2022 and bottomed at -$15.4 million in Q4 2021.